Title of article :
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
Author/Authors :
J. Ruiz، نويسنده , , A. Morabia، نويسنده , , H. Blanche، نويسنده , , R. W. James، نويسنده , , M-C. B. Garin، نويسنده , , G. Charpentier، نويسنده , , Ph Passa، نويسنده , , C. Vaisse، نويسنده , , J. Ruiz، نويسنده , , Ph Froguel، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 1995
Pages :
4
From page :
869
To page :
872
Abstract :
Paraoxonase is a high-density-lipoprotein-associated enzyme capable of hydrolysing lipid peroxides. Thus it might protect lipoproteins from oxidation. It has two isoforms, which arise from a glutamine (A isoform) to arginine (B isoform) interchange at position 192. The relevance of this polymorphism to coronary heart disease (CHD) in non-insulin-dependent diabetic patients was investigated in case-control study. Of the 434 patients, 171 had confirmed coronary artery disease; the other 263 had no history of such disease. The B allele and AB+BB genotypes were associated with an increased risk of coronary heart disease. Compared with subjects homozygous for the A allele (AA genotype), the odds ratio of CHD for subjects homozygous for the B allele was 2·5 (95% Cl 1·2-5·3) and that for those heterozygous for the B allele was 1·6 (95% CI 1·1-2·4), suggesting a co-dominant effect on cardiovascular risk. When subjected to multivariate analysis, the B allele remained significantly associated with CHD (odds ratio 1·94, P=0·03). The paraoxonase gene polymorphism is thus an independent cardiovascular risk factor in non-insulin-dependent diabetic patients. A possible explanation for this finding is that activity of the paraoxonase B isotype does not protect well against lipid oxidation, a major atherogenic pathway.
Journal title :
The Lancet
Serial Year :
1995
Journal title :
The Lancet
Record number :
563045
Link To Document :
بازگشت